3/24
06:40 am
zyme
Zymeworks Announces Participation in Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Zymeworks Announces Participation in Upcoming Investor Conferences [Yahoo! Finance]
3/24
06:13 am
zyme
Zymeworks Announces Participation in Upcoming Investor Conferences [TheStreet.com]
Low
Report
Zymeworks Announces Participation in Upcoming Investor Conferences [TheStreet.com]
3/24
06:00 am
zyme
Zymeworks Announces Participation in Upcoming Investor Conferences
Low
Report
Zymeworks Announces Participation in Upcoming Investor Conferences
3/18
08:13 am
zyme
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting [Yahoo! Finance]
Low
Report
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting [Yahoo! Finance]
3/18
07:46 am
zyme
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
Low
Report
Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting
3/17
05:45 pm
zyme
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting [Yahoo! Finance]
Low
Report
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting [Yahoo! Finance]
3/17
05:02 pm
zyme
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
Low
Report
Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting
3/6
08:03 am
zyme
Zymeworks (ZYME) had its price target raised by HC Wainwright from $32.00 to $46.00. They now have a "buy" rating on the stock.
Medium
Report
Zymeworks (ZYME) had its price target raised by HC Wainwright from $32.00 to $46.00. They now have a "buy" rating on the stock.
3/3
01:06 pm
zyme
Zymeworks (ZYME) had its price target raised by Stifel Nicolaus from $40.00 to $47.00. They now have a "buy" rating on the stock.
Low
Report
Zymeworks (ZYME) had its price target raised by Stifel Nicolaus from $40.00 to $47.00. They now have a "buy" rating on the stock.
3/3
11:24 am
zyme
Zymeworks (ZYME) had its price target raised by Leerink Partners from $52.00 to $58.00. They now have an "outperform" rating on the stock.
Low
Report
Zymeworks (ZYME) had its price target raised by Leerink Partners from $52.00 to $58.00. They now have an "outperform" rating on the stock.
3/2
09:28 pm
zyme
Zymeworks outlines $1.5B milestone potential and signals milestone-driven expansion strategy through 2028 [Seeking Alpha]
Medium
Report
Zymeworks outlines $1.5B milestone potential and signals milestone-driven expansion strategy through 2028 [Seeking Alpha]
3/2
12:52 pm
zyme
Zymeworks Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Zymeworks Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
3/2
10:55 am
zyme
Zymeworks Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Zymeworks Q4 Earnings Call Highlights [Yahoo! Finance]
3/2
06:18 am
zyme
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing [Yahoo! Finance]
Low
Report
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing [Yahoo! Finance]
3/2
06:01 am
zyme
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
Low
Report
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing
3/2
06:00 am
zyme
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Low
Report
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
2/12
06:00 am
zyme
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
Low
Report
Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026
1/27
06:00 am
zyme
Zymeworks Announces Participation in Upcoming Investor Conferences
Low
Report
Zymeworks Announces Participation in Upcoming Investor Conferences
1/23
05:09 am
zyme
Zymeworks (NASDAQ:ZYME) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Zymeworks (NASDAQ:ZYME) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/12
06:17 am
zyme
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy [Yahoo! Finance]
Low
Report
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy [Yahoo! Finance]
1/12
06:00 am
zyme
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
Low
Report
Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy
1/11
07:40 pm
zyme
Zymeworks Outlines Strategic Priorities and Outlook for 2026 [Yahoo! Finance]
Low
Report
Zymeworks Outlines Strategic Priorities and Outlook for 2026 [Yahoo! Finance]
1/11
06:00 pm
zyme
Zymeworks Outlines Strategic Priorities and Outlook for 2026
Low
Report
Zymeworks Outlines Strategic Priorities and Outlook for 2026
1/6
02:47 pm
zyme
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit [Yahoo! Finance]
Low
Report
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit [Yahoo! Finance]
1/6
01:34 pm
zyme
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
Low
Report
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit